Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 117Neoplasms 101Prostatic Neoplasms 76Carcinoma, Non-Small-Cell Lung 75Colorectal Neoplasms 73Carcinoma, Hepatocellular 67Leukemia, Myeloid, Acute 59Stomach Neoplasms 52Neoplasm Metastasis 50Lung Neoplasms 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Pancreatic Neoplasms 40Recurrence 36Head and Neck Neoplasms 32Rectal Neoplasms 30Colonic Neoplasms 30Leukemia 29Multiple Myeloma 28Ovarian Neoplasms 26Lymphoma 25Squamous Cell Carcinoma of Head and Neck 24Hematologic Neoplasms 23Melanoma 22Urinary Bladder Neoplasms 20Liver Neoplasms 20Polycystic Ovary Syndrome 19Myelodysplastic Syndromes 19Lymphoma, Large B-Cell, Diffuse 19Esophageal Neoplasms 19Uterine Cervical Neoplasms 16

Interventions

sitravatinib 1pembrolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Advanced or Metastatic Solid Malignancies × Clear all
NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Mirati Therapeutics Inc.

Phase 2/3 Completed
52 enrolled

Advanced or Metastatic Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡